The biotech rally seems to be far from over as clinical studies advance, FDA Approvals are turning quicker and new associations leading to numerous therapeutic advantages are taking hold for firms such as MannKind Corporation (NASDAQ:MNKD), Therapix Biosciences Ltd. – American Depositary Shares (NASDAQ:TRPX), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Canopy Growth Corporation (OTCMKTS:TWMJF) and Aptevo Therapeutics Inc (NASDAQ:APVO).
Oppenheimer’s Leah Rush Cann issued a publication on Barron’s writing Biotech equities, that still remain extremely undervalued, with a positive outlook that comes on the back of the biotech sector has recorded a 17.7% jump this year through September. Her stance is that the sector is demonstrating ‘increasing strength’.
MannKind recently reported that the U.S. FDA has permitted an update to the Afrezza prescribing data to include new clinical information that was demonstrated at the American Diabetes Association Scientific Sessions in this June. Afrezza inhalation powder is permitted by the FDA to enhance glycemic control in adult people with type 1 and type 2 diabetes mellitus. The drug is the only inhaled fast-acting mealtime insulin available in the U.S. Afrezza is dosed at the starting of a meal and commences to appear in the blood in nearly one minute
Therapix Biosciences, a specialty, clinical-stage pharmaceutical firm focusing on the advancement of cannabinoid-based treatments, reported that it has finalized a deal with Catalent Pharma Solutions, the major international provider of advanced delivery technologies and advancement solutions for biologics, drugs and consumer health offerings, for the formulation, clinical manufacturing and development of THX-TS01.
Pursuant to the deal, Catalent will advance THX-TS01 in softgel form in back of Therapix’s clinical development plan and in accordance with cGMP. The formulation, analytical, development and cGMP manufacturing activities will be planned at Catalent’s primary softgel advancement and manufacturing facility in St. Petersburg, Florida.
In the last trading session, the stock price of MannKind gained more than 1% to close the day at $5.03.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.